SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression
Clinical trial NCT05498636 · UNKNOWN
Trial details
- NCT number
- NCT05498636
- Sponsor
- The Affiliated Hospital of Qingdao University
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2025-07-30
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.